Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B

Table 2 Differences between 30 patients treated with adefovir dipivoxil with/without proximal kidney tubular dysfunction n (%)

	PKTD (-)	PKTD (+)	P value
	(n = 21)	(n = 9)
Age (yr)
At the initiation of ADV	52.1 ± 9.3	59.0 ± 9.7	NS
At the evaluation of PKTD	56.0 ± 9.1	65.7 ± 8.6	0.012
Male/female	16/5	5/4	NS
BMI (kg/m2)	23.3 ± 3.0	20.8 ± 2.5	0.038
Current smokers	4 (19.0)	0	NS
Habitual drinkers	2 (9.5)	0	NS
Hypertension	9 (42.9)	3 (33.3)	NS
Diabetes	1 (4.8)	1 (11.1)	NS
Treatment duration of NA (mo)	104.1 ± 32.1	115.1 ± 25.2	NS
Treatment duration of ADV (mo)	56.0 ± 33.5	86.0 ± 21.8	0.021
SLC22A6 (hOAT1) 4531 G/A,
G/G	13 (61.9)	4 (44.4)	NS
G/A	8 (38.1)	4 (44.4)
A/A	0	1 (11.1)
ABCC2 (MRP2) -24 C/T, rs717620
C/C	12 (57.1)	5 (55.6)	NS
C/T	5 (23.8)	4 (44.4)
T/T	4 (19.0)	0
eGFR (mL/min per 1.73 m2)
At the initiation of ADV	81.4 ± 11.6	77.1 ± 17.0	NS
At the evaluation of PKTD	70.0 ± 10.9	46.9 ± 15.8	< 0.001

¹Variant position is relative to accession No. AJ249369. Data are shown as mean ± SD or percentage. Overall P values were calculated by unpaired t-test or χ²-test. PKTD: Proximal kidney tubular dysfunction; ADV: Adefovir dipivoxil; BMI: Body mass index; NA: Nucleos(t)ide analogue; hOAT1: Human organic anion transporter 1; MRP2: Multidrug-resistance protein 2; eGFR: Estimated glomerular filtration rate; NS: Not significant.